Monoclonal antibody treatment drives rapid culture conversion in SARS-CoV-2 infection

  1. Julie Boucau
  2. Kara W. Chew
  3. Manish C. Choudhary
  4. Rinki Deo
  5. James Regan
  6. James P. Flynn
  7. Charles R. Crain
  8. Michael D. Hughes
  9. Justin Ritz
  10. Carlee Moser
  11. Joan A. Dragavon
  12. Arzhang C. Javan
  13. Ajay Nirula
  14. Paul Klekotka
  15. Alexander L. Greninger
  16. Robert W. Coombs
  17. William A. Fischer
  18. Eric S. Daar
  19. David A. Wohl
  20. Joseph J. Eron
  21. Judith S. Currier
  22. Davey M. Smith
  23. Jonathan Z. Li
  24. Amy K. Barczak

Reviewed by

Read the full article See related articles

Listed in

Log in to save this article

Abstract

No abstract available

Article activity feed

  1. Version published to 10.1016/j.xcrm.2022.100678
  2. ScreenIT

    SciScore for 10.1101/2021.12.25.21268211: (What is this?)

    Please note, not all rigor criteria are appropriate for all manuscripts.

    Table 1: Rigor

    Ethicsnot detected.
    Sex as a biological variablenot detected.
    RandomizationStudy participants: ACTIV-2 is a multi-center randomized, blinded placebo-controlled phase 2/3 platform trial in non-hospitalized adults4.
    BlindingStudy participants: ACTIV-2 is a multi-center randomized, blinded placebo-controlled phase 2/3 platform trial in non-hospitalized adults4.
    Power Analysisnot detected.
    Cell Line Authenticationnot detected.

    Table 2: Resources

    Experimental Models: Cell Lines
    SentencesResources
    Briefly, Vero-E6 cells were maintained in Dulbecco’s Modified Eagle Medium (DMEM) supplemented with HEPES, Penicillin/Streptomycin, Glutamine, and 10%
    Vero-E6
    suggested: None
    Software and Algorithms
    SentencesResources
    Statistics/Calculations: Statistical analyses were performed using PRISM software v9.2.0.
    PRISM
    suggested: (PRISM, RRID:SCR_005375)

    Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).

    Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

    Results from TrialIdentifier: We found the following clinical trial numbers in your paper:

    IdentifierStatusTitle
    NCT04518410RecruitingACTIV-2: A Study for Outpatients With COVID-19

    Results from Barzooka: We did not find any issues relating to the usage of bar graphs.

    Results from JetFighter: We did not find any issues relating to colormaps.

    Results from rtransparent:
    • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
    • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
    • No protocol registration statement was detected.

    Results from scite Reference Check: We found no unreliable references.

    About SciScore

    SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

  3. Version published to 10.1101/2021.12.25.21268211v1 on medRxiv